About Apollomics, Inc.
https://www.apollomicsinc.comApollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia.
CEO
Hung-Wen Chen
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 26, 2021
Method of going public SPAC
Full time employees 13
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-11-25 | Reverse | 1:100 |
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $24.85 M
52w High $42.12
52w Low $3.66
P/E -0.77
Volume 18.47K
Outstanding Shares 1.10M
About Apollomics, Inc.
https://www.apollomicsinc.comApollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $8.5M ▲ | $19.11M ▲ | $-12.54M ▲ | -147.48% ▼ | $-11.37 ▲ | $-12.5M ▲ |
| Q4-2024 | $-1.57M ▼ | $15.26M ▼ | $-18.65M ▲ | 1.19K% ▲ | $-16.92 ▲ | $-15.78M ▲ |
| Q2-2024 | $1.77M ▲ | $27.08M ▼ | $-35.21M ▼ | -1.99K% ▲ | $-37.56 ▼ | $-25.28M ▲ |
| Q4-2023 | $333K ▼ | $28.66M ▲ | $-21.91M ▲ | -6.58K% ▲ | $-0.24 ▲ | $-27.82M ▼ |
| Q2-2023 | $488K | $26.17M | $-150.69M | -30.88K% | $-2.56 | $-25.62M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $2.09M ▼ | $11.12M ▼ | $15.52M ▲ | $-4.4M ▼ |
| Q4-2024 | $9.77M ▼ | $13.1M ▼ | $8.23M ▼ | $4.86M ▼ |
| Q2-2024 | $25.93M ▼ | $34.57M ▼ | $13.77M ▼ | $20.81M ▼ |
| Q4-2023 | $37.82M ▼ | $55.39M ▼ | $14.15M ▼ | $41.23M ▼ |
| Q2-2023 | $52.62M | $71.38M | $15.68M | $55.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2024 | $-18.65M ▲ | $-12.76M ▲ | $236K ▼ | $-3.65M ▼ | $0 | $-12.76M ▲ |
| Q2-2024 | $-35.21M ▼ | $-15.99M ▲ | $5.75M ▼ | $4.12M ▲ | $0 | $-16.01M ▲ |
| Q4-2023 | $-21.91M ▲ | $-18.81M ▲ | $21.61M ▲ | $3.98M ▼ | $0 | $-18.81M ▲ |
| Q2-2023 | $-150.69M ▲ | $-24.4M ▼ | $-242K ▼ | $17.24M ▲ | $0 ▲ | $-24.4M ▼ |
| Q4-2022 | $-237.39M | $-23.1M | $5.21M | $-141K | $-50.7M | $-23.13M |
CEO
Hung-Wen Chen
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 26, 2021
Method of going public SPAC
Full time employees 13
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-11-25 | Reverse | 1:100 |
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0